Story perspectives

Medicare Approves Eli Lilly's Zepbound for Sleep Apnea

1/9/2025

46 5

Summary

Story summary

Eli Lilly's Zepbound is now covered by Medicare for obstructive sleep apnea, increasing accessibility despite its $1,000 monthly cost.
The FDA's approval aligns with Medicare's rules for drugs with accepted medical uses.
Analysts are optimistic about Eli Lilly's long-term growth in the obesity treatment market, despite recent stock declines.
The company is enhancing manufacturing capabilities and exploring new therapeutic areas for portfolio diversification.

1 of 1

Story summary

Eli Lilly's Zepbound is now covered by Medicare for obstructive sleep apnea, increasing accessibility despite its $1,000 monthly cost.
The FDA's approval aligns with Medicare's rules for drugs with accepted medical uses.
Analysts are optimistic about Eli Lilly's long-term growth in the obesity treatment market, despite recent stock declines.
The company is enhancing manufacturing capabilities and exploring new therapeutic areas for portfolio diversification.